Lixisenatide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. It is a 44-amino acid peptide analog of exendin-4, a peptide first identified in the venom of the Gila monster. The discovery of exendin-4’s potent and prolonged GLP-1-like activity led to the development of lixisenatide, which is engineered to resist degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), thereby extending its duration of action. Its significance lies in its role as a once-daily injectable therapy that enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety, addressing multiple pathophysiological defects in type 2 diabetes.
Quick Facts
| Also Known As | AVE0010, ZP10A, GLP-1 receptor agonist, Glucagon-like peptide-1 analog |
|---|---|
| Sequence | H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Molecular Formula | C215H347N61O65S |
| Molecular Weight | 4858 Da |
| PubChem CID | 90472060 |
Research Parameters
| Half-Life | ~2-4 hours |
|---|---|
| Stability | The commercial product (Adlyxin) is supplied as a solution for injection. For research-grade lyophilized material, stability data is manufacturer-specific. Typically, lyophilized peptides are stable for 24 months when stored at -20°C. After reconstitution with the recommended solvent, the solution should be stored at 2-8°C and used within a timeframe specified by the manufacturer (often 28 days). |
| Solubility | Bacteriostatic Water or Sterile Water for Injection |
| Storage (Lyophilized) | -20°C, protect from light and moisture |
| Storage (Reconstituted) | 2-8°C (refrigerated), protect from light |
| Typical Research Dose | 10-20 mcg |
| Cycle Parameters | In clinical research, daily subcutaneous injection, often with a two-week titration period from 10 mcg to 20 mcg, continued for the study duration (e.g., 24 weeks). |
| Amino Acid Count | 41 |
Mechanism of Action
Lixisenatide acts primarily as a potent and selective agonist at the glucagon-like peptide-1 (GLP-1) receptor. Binding to this G-protein coupled receptor initiates several intracellular signaling pathways that collectively improve glycemic control.
cAMP/PKA Pathway: Lixisenatide binding activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP). This activates protein kinase A (PKA), which in turn promotes the exocytosis of insulin-containing granules from pancreatic beta-cells in a glucose-dependent manner.
Glucagon Suppression: Via the same receptor signaling in pancreatic alpha-cells, lixisenatide inhibits the secretion of glucagon, particularly in the postprandial state, reducing hepatic glucose production.
Gastric Emptying: Activation of GLP-1 receptors in the stomach and central nervous system significantly delays gastric emptying, which slows the rate of nutrient absorption and reduces postprandial glucose excursions.
Central Satiety: GLP-1 receptor agonism in the hypothalamus and brainstem promotes feelings of satiety and reduces food intake, contributing to potential weight loss or weight neutrality.
Research Applications
Glycemic Control in Type 2 Diabetes: Lixisenatide has been extensively studied for its ability to lower blood glucose levels, particularly postprandial glucose. Clinical trials demonstrate significant reductions in HbA1c, with a pronounced effect on postprandial hyperglycemia due to its strong inhibition of gastric emptying.
Cardiovascular Outcomes: Large-scale outcome trials have investigated the cardiovascular safety of lixisenatide. Research indicates it does not increase the risk of major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk, providing evidence of its safety profile in this population.
Weight Management: As a GLP-1 receptor agonist, lixisenatide promotes mild to moderate weight loss in clinical studies through its effects on satiety and gastric emptying, making it a compound of interest in obesity research alongside its glycemic benefits.
Beta-cell Function: Preclinical and clinical research suggests that, like other GLP-1 agonists, lixisenatide may have protective effects on pancreatic beta-cells, potentially improving insulin secretory capacity and promoting beta-cell proliferation while inhibiting apoptosis.
Safety & Side Effects
The most commonly reported side effects in clinical trials are gastrointestinal, including nausea, vomiting, and diarrhea, which are generally mild to moderate and tend to diminish over time. Hypoglycemia is a risk, particularly when used in combination with insulin or sulfonylureas. Injection site reactions have also been reported. Anecdotal reports from clinical use align with these trial findings. Theoretical concerns, as with all GLP-1 agonists, include a potential risk of pancreatitis and medullary thyroid carcinoma based on rodent studies, although a causal link in humans has not been established.
Dosage Information
Disclaimer: The following information is derived from published clinical research studies and is presented for educational and research purposes only. It does not constitute medical advice.
In clinical trials for type 2 diabetes, lixisenatide is typically administered as a once-daily subcutaneous injection. The dose is titrated: starting at 10 mcg once daily for two weeks, then increased to a maintenance dose of 20 mcg once daily. It is injected within one hour before the first main meal of the day. Study durations have ranged from 24 weeks to several years in long-term outcome trials.
References
Ratner, R.E., et al. 'Cardiovascular safety of lixisenatide in patients with type 2 diabetes: a meta-analysis of adjudicated cardiovascular outcomes in phase 2 and 3 trials.' Diabetes Care, 2016.
Rosenstock, J., et al. 'Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).' Diabetic Medicine, 2013.
Pratley, R.E., et al. 'Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week randomized, open-label, active-controlled study (GetGoal-X).' Diabetes Care, 2014.
Fonseca, V.A., et al. 'Reductions in systolic blood pressure with lixisenatide in patients with type 2 diabetes: insights from a patient-level pooled analysis of 10 randomized trials.' Journal of the American Society of Hypertension, 2016.
Meier, J.J., et al. 'Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.' Diabetologia, 2011. (Note: This reference discusses GLP-1 mechanisms; for lixisenatide-specific action, see Rosenstock 2013).
Pfeffer, M.A., et al. 'Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.' The New England Journal of Medicine, 2015.